Circulating tumor cells are the transferred cancer cells. When the tumor cells derive from the primary tumor to vascular system, the circulating tumor cells will migrate to the other organs and induce pathological changes, if the immune cells did not identify and eliminate the circulating tumor cells. Therefore, the tumor metastasis can be prevented by the circulating tumor cells testing.
FHB constructs a complete screening platform for circulating tumor cells based on intensive research. We utilize the advanced flow cytometer and epitope-specific monoclonal antibodies to accurately identify circulating tumor cells. With the combination of circulating tumor cell analysis and immune-check point analysis (e.g. mutant EGFR, VEGFR1-3 and PD-L1). FHB is able to provide a consummate personalized medical strategy.
